Pretreatment serum monocyte chemoattractant protein-1 as a predictor of long-term outcome by ustekinumab in patients with Crohn's disease.
Hiroaki OkudaShuhei HosomiShigehiro ItaniNoriyuki KurimotoYumie KobayashiRieko NakataYu NishidaMasaki OminamiYuji NadataniShusei FukunagaKoji OtaniNoriko KamataFumio TanakaYasuaki NagamiKoichi TairaSatoko OhfujiYasuhiro FujiwaraPublished in: Journal of gastroenterology and hepatology (2023)
Our findings suggest that pre-treatment serum MCP-1 analysis, combined with a history of biologic use could be a novel biomarker for predicting the long-term efficacy of ustekinumab in patients with Crohn's disease.